Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma

In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed how on-body subcutaneous administration methods could allow for select at-home administration of therapies for patients with multiple myeloma. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a clinical member of the Cancer Prevention, Control and Population Research Program at Case Comprehensive Cancer Center in Ohio. Dr Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Rochester, Minnesota.

In the final episode of a 3-part series, Drs Faiman and Ailawadhi explained how they are integrating on-body administration of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection into clinical practice following its July 2026 FDA approval, and the pair also shared how this method could represent a strategy for at-home treatment within the United States in the future.

In the first episode, Drs Faiman and Ailawadhi detailed the transition to subcutaneous administration of anti-CD38 monoclonal antibodies in multiple myeloma management. And in the second episode, they broke down how patient-centric treatment methods are a key focus in myeloma research.